Rowan Mesilhy

Dr. Rowan Mesilhy


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024
Verified
Book Chapter
Open access
PDF file
SHSalma Hegazi
Salma Hegazi
RARoaa Aly
Roaa Aly
RMRowan Mesilhy
Rowan Mesilhy
HAHesham Aljohary
Hesham Aljohary
This chapter digs into the complexities of diabetic foot ulcer (DFU) wound healing, encompassing cellular responses from fibroblasts, keratinocytes, and macrophages, as well as humoral responses involving the release of growth factors and cytokines. The normal wound healing process is hindered in diabetics by factors like infections, venous insufficiency, impaired oxygenation, age-related changes, immune dysfunction, and a dry environment, contributing to delayed and challenging wound healing. The discussion then focuses on the intricate interplay of signaling cascades, including PI3K/Akt, MAPK/ERK, and Wnt/β-catenin, in the pathology of DFUs. Diabetes induces disruptions in the PI3K/Akt pathway, impeding cell migration and angiogenesis due to compromised insulin signaling and increased oxidative stress. Abnormalities in the MAPK pathway, essential for inflammation and tissue remodeling, further impact wound closure in DFUs. Additionally, downregulation of the Wnt/β-catenin pathway, crucial for tissue regeneration, contributes to immune dysfunction, delaying healing in diabetic wounds. Finally, the chapter explores multifaceted factors contributing to the pathogenesis of DFUs, including epigenetic modifications, oxidative stress, advanced glycation end products (AGEs), the polyol pathway, diacylglycerol-protein kinase C (DAG-PKC) activation, and the nitric oxide (NO) pathway. Persistent hyperglycemia in diabetes hinders wound healing, causing chronic ulcers and complications. Addressing these mechanisms is crucial for revolutionizing management.

1 July 2024
Verified
Book Chapter
Closed access
PDF file
DYDuaa Yousif
Duaa Yousif
RMRowan Mesilhy
Rowan Mesilhy
RARoaa Aly
Roaa Aly
SHSalma Hegazi
Salma Hegazi
ZYZahra Yousif
Zahra Yousif
AAAbdallah Musa Abdallah
Abdallah Musa Abdallah

12 September 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
RMRowan Mesilhy
Rowan Mesilhy
ISIbrahim Safra
Ibrahim Safra
SAShaikha Alnaimi
Shaikha Alnaimi
AAAlaa Awadullah Mohammed Ali
Alaa Awadullah Mohammed Ali
RTRayan Terkawi
Rayan Terkawi
AGAshraf Gad
Ashraf Gad
Background: Early-onset neonatal meningitis (EONM) is a rare but serious condition where antibiotics are often given for extended periods, even without a positive cerebrospinal fluid (CSF) culture. The reasons for this prolonged treatment are unknown. Methodology: This study, conducted at the Women’s Wellness and Research Center, Doha, retrospectively analyzed the determinants of prolonged antibiotic therapy among neonates with sterile CSF cultures during the first week of life, born during 2015 to 2018. Results: Of 315 neonates without confirmed meningitis, 96 (30.5%) received prolonged antibiotic therapy. These infants had significantly lower birth weights (2790 g vs. 3170 g) and gestational ages (36.7 weeks vs. 38.5 weeks). They were more likely to require respiratory support, appear ill, and have laboratory abnormalities, including neutropenia, positive blood cultures (36.5% vs. 0.9%), elevated C-reactive protein (CRP), and higher CSF protein. Multivariable analysis identified low Apgar scores (Adjusted Odds Ratio (aOR), 2.82), positive blood cultures (aOR, 118.48), traumatic lumbar puncture (LP) (aOR, 2.14), CRP levels ≥ 50 mg/L (aOR, 2.60), delayed LP (OR, 8.28), and elevated cerebrospinal fluid white cell counts (aOR, 5.47) as independent predictors of prolonged antibiotic use. Conclusions: Prolonged antibiotic use in neonates with sterile CSF cultures and suspected EONS is common and may be driven by certain clinical and laboratory indicators of illness severity and inflammation. Identifying these predictors can support risk-stratified treatment decisions, promoting safer antimicrobial stewardship.

15 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
SMShehab Fareed Mohamed
Shehab Fareed Mohamed
AMAli Mohamed
Ali Mohamed
MMmohamed mudarres
mohamed mudarres
AAAZZA ELFADIL ABBAS ABDALLA
AZZA ELFADIL ABBAS ABDALLA
AAAbdulrahman Al-Mashdali
Abdulrahman Al-Mashdali
GBGautam Borthakur
Gautam Borthakur
Background: BRAF is a core component of the RAS–MAPK signaling pathway and an established oncogenic driver in several solid tumors and selected hematologic malignancies. In myeloid neoplasms, BRAF mutations are rare, and their prevalence, molecular context, and clinical significance remain incompletely defined. Available evidence is scattered across heterogeneous reports involving acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, and overlap myelodysplastic/myeloproliferative neoplasms, with variable descriptions of mutation subtypes, co-mutational profiles, cytogenetic associations, therapeutic approaches, and clinical outcomes. To address these gaps, this review synthesizes data from the published literature up to 2025, summarizing the distribution, genetic landscape, and clinical impact of molecularly confirmed BRAF mutations across the spectrum of myeloid neoplasms. Results: Across published cohorts, BRAF mutations occurred in less than 1% of unselected myeloid neoplasms, with enrichment in chronic myelomonocytic leukemia and therapy-related or secondary acute myeloid leukemia. Both V600E and non-V600E variants were observed, typically within a complex genomic background involving ASXL1, TET2, DNMT3A, SRSF2, and RAS-pathway mutations. Acute myeloid leukemia cases showed poor prognosis, with median overall survival measured in months, whereas myelodysplastic syndromes and chronic myelomonocytic leukemia demonstrated relatively longer survival. Targeted MAPK inhibition produced hematologic responses in selected cases but rarely resulted in durable molecular clearance. Conclusions: BRAF mutations in myeloid neoplasms are rare, heterogeneous, and usually represent secondary events in clonal evolution. Although mutation clearance appears prognostically relevant, current targeted approaches provide limited durability, underscoring the need for prospective studies in this setting.

1 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
RMRowan Mesilhy
Rowan Mesilhy
ZNZainab Nurulhaque
Zainab Nurulhaque
PBPatrick G. Burgon
Patrick G. Burgon
Shona Dr. Shona PedersenShona Dr. Shona Pedersen
Shona Dr. Shona Pedersen
RSRafif Mahmood AL Saady
Rafif Mahmood AL Saady
Apolipoprotein A (ApoA), an integral component of high-density lipoprotein (HDL) particles, plays a vital role in the transport and metabolism of lipids. It is implicated in both cardiovascular (CVD) and neurological diseases. In the context of CVD, ApoAs are pivotal in facilitating the reverse transport of cholesterol, mitigating inflammation, and preserving endothelial function. These char- acteristics highlight the crucial role of ApoA in averting the onset of CVDs. Moreover, ApoA has been implicated in the pathogenesis of several diseases, such as Alzheimer's disease (AD), Parkin- son's disease (PD), and multiple sclerosis (MS). Apart from its role in lipid metabolism, recent stud- ies have indicated the involvement of ApoA in neuroprotection, amyloid-beta clearance, and regu- lation of neuroinflammation. This paper addresses the research question: "How do different isoforms of Apolipoprotein A influence the development and progression of cardiovascular and neurological diseases, and what are the potential therapeutic implications of targeting ApoA in these conditions?" By providing a comprehensive review of current knowledge, this paper empha- sizes the importance of ApoA in understanding the intricate connections between cardiovascular and neurological health, suggesting that ApoA-targeted interventions may help treat diseases in both domains.

29 November 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RMRowan Mesilhy
Rowan Mesilhy
MKMuhammad Naseem Khan
Muhammad Naseem Khan
ASAsma Syed
Asma Syed
RHRazan Hourani
Razan Hourani
HCHonar Cherif
Honar Cherif
SMShehab F. Mohamed
Shehab F. Mohamed
Therapy-related acute lymphoblastic leukemia (t-ALL) is an aggressive subtype of ALL that arises after cytotoxic therapy. It is associated with adverse cyt